Yi, Jing

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 2,756

Cancer cell killing via ROS: To increase or decrease, that is the question

Wang, J., & Yi, J. (2008) · Cancer Biology & Therapy

Redox biology and oxidative stressCancer and biochemical research

Cited by 790

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009) · The Oncologist

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 239

LGR6 Is a High Affinity Receptor of R-Spondins and Potentially Functions as a Tumor Suppressor

Gong, X., Carmon, K. S., Lin, Q., Thomas, A., Yi, J., & Liu, Q. (2012) · PLoS ONE

Wnt/β-catenin signaling in development and cancerReceptor Mechanisms and Signaling

Cited by 129